The rapid rise of GLP-1 receptor agonist medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro) — has produced a new and growing aesthetic concern. Rapid weight loss accelerates the very facial volume depletion that is normally associated with ageing, producing sunken cheeks, deepened nasolabial folds, and skin laxity in patients who may otherwise look younger than their years. The aesthetics industry is responding with both clinical evidence and new treatment protocols.
Why Rapid Weight Loss Ages the Face
Facial ageing involves two parallel processes: loss of tissue support (bone, fat, muscle) and changes in skin quality. Gradual, age-related weight change allows the skin some degree of adaptation. Rapid weight loss — particularly the significant reductions that GLP-1 medications can produce, often 15–20% of body weight over 12 months — outpaces the skin's ability to remodel, leaving stretched, deflated tissue over a structurally depleted framework.
The facial fat compartments most affected are typically those of the mid-face — the medial and lateral cheek fat pads — and the buccal fat, which, when lost rapidly, produces the sunken, angular appearance that social media has termed "Ozempic face". The temporal hollowing and periorbital volume loss that accompany it can make a patient appear significantly older than their weight loss might suggest they would look. The irony is not lost on clinicians: patients losing weight for health and appearance reasons find that the face, which cannot easily be exercised, ages disproportionately in the process.
What the Clinical Evidence Shows
Galderma has been at the forefront of building the clinical evidence base for addressing medication-driven weight loss with its injectable portfolio. In 2024 and 2025, the company presented a series of studies examining the use of Restylane and Sculptra to restore facial volume and skin quality in patients who had undergone significant GLP-1-driven weight loss. The data demonstrated meaningful improvements in facial fullness, nasolabial fold depth, and patient-reported satisfaction with facial appearance — results that were maintained at nine-month follow-up.
The approach typically combines a biostimulator — Sculptra, to regenerate the deep collagen framework — with a targeted HA filler programme addressing the specific fat compartments most depleted. Profhilo may also be incorporated to address the dermal skin quality changes. This multi-layer protocol acknowledges that GLP-1-related facial ageing is a composite problem requiring a composite solution.
What Patients on GLP-1 Medications Should Know
If you are taking or planning to take a GLP-1 medication, a pre-emptive aesthetic consultation is worth considering. Patients who begin aesthetic treatment — particularly biostimulators — alongside or slightly before significant weight loss are better positioned to maintain their facial appearance through the transition than those who address the changes after the fact. The response to biostimulators like Sculptra and Profhilo is enhanced in well-hydrated, nutritionally supported tissue — something that patients losing weight rapidly may need to pay particular attention to.
There is also a straightforward timing principle: the face responds better to volume restoration when there is tissue to support the treatment. Attempting to replace significant volume in severely depleted, lax tissue produces different — and generally less satisfying — results than maintaining volume proactively. If you are on GLP-1 medication and noticing changes in your facial appearance, an honest, no-obligation consultation with Tracy will help establish what is possible and what approach makes sense at your current stage.
A New Normal for Aesthetic Practice
GLP-1 medications are projected to be among the most widely prescribed drugs globally within the next five years. For aesthetic medicine, this represents both a clinical challenge and a patient education opportunity. The practitioners best placed to serve this growing patient group will be those who understand the specific pattern of GLP-1-related facial changes, have the product knowledge to address them appropriately, and can advise on timing and sequencing with the confidence that comes from genuine clinical experience.